Figure 3.
Arithmetic mean anti-FXa activity vs time on day 6 after the last dose of rivaroxaban or edoxaban following andexanet alfa/placebo administration. (A) Rivaroxaban studies (cohorts 1-3, upper left panel; cohorts 4-5, upper right panel). Andexanet alfa was dosed at 3 hours after the last dose of rivaroxaban. (B) Edoxaban studies (cohorts 1-2, lower left panel; cohort 3, lower right panel). Andexanet alfa was administered at 3 hours (cohorts 1-2) or 5 hours (cohort 3) after the last dose of edoxaban.

Arithmetic mean anti-FXa activity vs time on day 6 after the last dose of rivaroxaban or edoxaban following andexanet alfa/placebo administration. (A) Rivaroxaban studies (cohorts 1-3, upper left panel; cohorts 4-5, upper right panel). Andexanet alfa was dosed at 3 hours after the last dose of rivaroxaban. (B) Edoxaban studies (cohorts 1-2, lower left panel; cohort 3, lower right panel). Andexanet alfa was administered at 3 hours (cohorts 1-2) or 5 hours (cohort 3) after the last dose of edoxaban.

Close Modal

or Create an Account

Close Modal
Close Modal